Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning or Failure) to Imatinib or Dasatinib: A Prospective, Multicenter, Pragmatic Clinical Trial
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Flumbatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms FINESTdm
- 12 Dec 2023 Results (n=94) assessing effectiveness and safety of switching to flumatinib in patients who have not achieved the optimal molecular response to imatinib or/and dasatinib, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 26 Jul 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 31 Dec 2020 New trial record